Nachrichten zur Ionis Pharmaceuticals Aktie

Geschäftstreiber: Der US-Biotech-Konzern Ionis Pharmaceuticals (IONS) hat sich auf die Entwicklung von Medikamenten und Therapien zur Behandlung von seltenen Erberkrankungen…

Ionis Pharmaceuticals ist ein führender Entwickler von Medikamenten, die auf der Antisense-Technologie basieren. Diese Technologie zielt darauf ab, die…

Key PointsIonis Pharmaceuticals (NASDAQ:IONS) reported Q2 2025 GAAP revenue and non-GAAP earnings per share that exceeded analyst expectations by wide…

· Recommendation based on Phase 3 Balance results, which showed a significant reduction of triglycerides and substantial reduction of acute…

Geschäftstreiber: Der US-Biotech-Konzern Ionis Pharmaceuticals (IONS) hat sich auf die Entwicklung von Medikamenten und Therapien zur Behandlung von seltenen Erberkrankungen…

Ionis Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progress…

Explore the exciting world of Kiniksa Pharmaceuticals (NASDAQ: KNSA) with our expert analysts in this Motley Fool Scoreboard episode. Check…

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…

Here is how Kiniksa Pharmaceuticals, Ltd. (KNSA) and Krystal Biotech, Inc. (KRYS) have performed compared to their sector so far…

The consensus price target hints at a 64.8% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this…

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…

The average of price targets set by Wall Street analysts indicates a potential upside of 58.6% in Kiniksa Pharmaceuticals (KNSA).…

Kiniksa Pharmaceuticals (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid…

Kiniksa Pharmaceuticals (KNSA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings…

The consensus price target hints at a 73.4% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this…

…

While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the…

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 41.07% and 65.19%, respectively, for the quarter ended December 2024. Do…

Ionis Pharmaceuticals beats Q4 estimates, guides 2025 revenue below consensus…

Evaluate the expected performance of Ionis Pharmaceuticals (IONS) for the quarter ended December 2024, looking beyond the conventional Wall Street…

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…

…

The mean of analysts price targets for Ionis Pharmaceuticals (IONS) points to a 55.9% upside in the stock. While this…

…

…

Kiniksa Pharmaceuticals (KNSA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that…

…

…

…

…

…

…

– Initiative aimed at improving access and outcomes for patients with recurrent pericarditis –…

…

…

Ionis Pharmaceuticals shares get boost by Oppenheimer, cites strong 2024…

Kyle Jenne returns to Ionis Pharmaceuticals as Executive VP…